Improved Adjusted EBITDA and Margins
Adjusted EBITDA was $49 million in Q1 2026 versus $37 million in Q1 2025; adjusted EBITDA margin improved to 6.8%, up 190 basis points year-over-year and up 30 basis points sequentially.
Quarterly New Business ACV Growth
Signed $114 million of new business ACV in Q1 2026, up 5% versus Q1 2025 and marking the sixth consecutive quarter of year-over-year ACV growth.
Larger Qualified Pipeline
Qualified ACV pipeline grew to $3.5 billion, up 10% year-over-year; Government pipeline up 27% YoY and Commercial pipeline 25% stronger than last quarter.
Strong Government Segment Performance
Government revenue increased 4.6% to $226 million; Government adjusted EBITDA was $59 million with a 26.1% margin, up 850 basis points year-over-year (including discrete benefits).
Commercial Margin Improvement Despite Revenue Pressure
Commercial adjusted EBITDA rose to $43 million with an adjusted EBITDA margin of 11.9%, up 190 basis points year-over-year, driven by cost efficiency and operational performance.
Sales Wins and Notable Contracts
Total Q1 sales wins exceeded $114 million, including >$48 million in Commercial (three long-standing health care clients) and >$66 million in Public Sector (including a $23 million Medicaid claims deal).
Cost Reduction Opportunity Identified
Management initiated a detailed cost review with external advisers and identified an initial opportunity to reduce $100 million of costs over the next 18 months; target of achieving EBITDA north of 10%.
Portfolio Optimization and Expected Divestiture Proceeds
Management expects proceeds from identified divestitures in 2026 to exceed $200 million, providing optionality for debt reduction, share repurchase or reinvestment.
Cash and Leverage Improvements
Ended Q1 2026 with approximately $251 million cash and net leverage of 2.8x; operating cash flow improved by $50 million year-over-year and adjusted free cash flow loss narrowed to $15 million.
Clear 2026–2027 Financial Targets
2026 revenue guidance of $2.8–$2.9 billion; adjusted EBITDA guidance $160–$190 million. 2027 outlook: flat-to-positive revenue with adjusted EBITDA of $190–$220 million and positive cash generation.
Progress on AI Initiatives
Active AI deployments (fraud and risk detection, GenAI agent assist 'Conni', workforce/productivity tools) producing client impacts and cost savings; management plans to scale AI use cases across Government and Commercial clients.